

ELIGIBILITY CRITERIA

The National Institute for Health and Clinical Excellence (NICE) has recommended that all psoriasis patients in the UK should be registered with us. The following is our eligibility criteria:



DIAGNOSIS OF PSORIASIS



WRITTEN INFORMED CONSENT



UNDER CARE OF A DERMATOLOGIST

TREATMENTS

Patient must be **starting** or **switching to** one of these drugs, **for treatment of their psoriasis**, in the **last 6 months** to be eligible for our conventional, biologic or small molecule cohorts:

CONVENTIONAL

- Acitretin
- Ciclosporin
- Fumaric acid esters
- Hydroxycarbamide
- Methotrexate
- Oral PUVA

BIOLOGIC

- Amgevita (Adalimumab biosimilar)
- Benepali (Etanercept biosimilar)
- Cimzia (Certolizumab pegol)
- Cosentyx (Secukinumab)
- Erelzi (Etanercept biosimilar)
- Hyrimoz (Adalimumab biosimilar)
- Ilumetri (tildrakizumab)
- Imraldi (Adalimumab biosimilar)
- Kyntheum (Brodalumab)
- Taltz (Ixekizumab)
- Tremfya (Guselkumab)
- Zessly (Infliximab biosimilar)

SMALL MOLECULE

- Skilarence (dimethyl fumarate)

PASI & DLQI

Conventional patients must have a **PASI of 10 or more** and a **DLQI of 11 or more** (unless switching between conventional therapies). There is no minimum score for biologic or small molecule patients (but we still require a PASI and DLQI).

Patients entering either the small molecule or conventional cohorts must be **naive to biologic therapy**.

